PDCD1 and neoplasm: Given the potential for enhanced tumor cell immunogenicity and T cell activation, inhibition of GSL synthesis through suppression of B3GNT5 expression may be implemented as a complementary approach along with current immunotherapeutic strategies, including PD-1 blockade [17].